The factors driving therapy resistance in diffuse glioma remain poorly understood. To
identify treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …

The evolutionary processes that drive universal therapeutic resistance in adult patients with
diffuse glioma remain unclear 1 , 2 . Here we analysed temporally separated DNA-…

Immune checkpoint inhibitors, including those targeting programmed cell death protein 1 (PD-1),
are reshaping cancer therapeutic strategies. Evidence suggests, however, that tumor …

Bladder cancer incurs a higher lifetime treatment cost than other cancers due to frequent
recurrence of non-invasive disease. Improved prognostic biomarkers and localized therapy are …

Patient-based cancer models are essential tools for studying tumor biology and for the
assessment of drug responses in a translational context. We report the establishment a large …

Patients with glioblastoma die from local relapse despite surgery and high-dose radiotherapy.
Resistance to radiotherapy is thought to be due to efficient DNA double-strand break (DSB…

Glioblastoma (GBM) is an aggressive cancer with a very poor prognosis. Generally viewed
as weakly immunogenic, GBM responds poorly to current immunotherapies. To understand …

The oncogene epidermal growth factor receptor variant III (EGFRvIII) is frequently expressed
in glioblastomas (GBM) but its impact on therapy response is still under controversial debate…

The cell surface proteome of tumors mediates the interface between the transformed cells
and the general microenvironment, including interactions with stromal cells in the tumor niche …

Current methods for resolving genetically distinct subclones in tumor samples require
somatic mutations to be clustered by allelic frequencies, which are determined by applying a …